Decoding tumor phenotypes for ALK, ROS1, and RET fusions in lung adenocarcinoma using a radiomics approach

Medicine (United States)

Volumn 94, Issue 41, 2015, Pages

  Yoon, Hyun Jung ^a,d   Sohn, Insuk ^b   Cho, Jong Ho ^a   Lee, Ho Yun ^a   Kim, Jae Hun ^a   Choi, Yoon La ^a   Kim, Hyeseung ^b   Lee, Genehee ^c   Lee, Kyung Soo ^a   Kim, Jhingook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; C ROS ONCOGENE 1; ONCOPROTEIN; PROTEIN RET; UNCLASSIFIED DRUG; FLUORODEOXYGLUCOSE F 18; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; RET PROTEIN, HUMAN; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; AGE; DIAGNOSTIC IMAGING; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PHENOTYPE; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84944459873     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001753     Document Type: Article

References (41)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
2. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6:1359-1366.
3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
4. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382-384.
5. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394.
6. Djalalov S, Beca J, Hoch JS, et al. Cost effectiveness of EML 4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol. 2014;32:1012-1019.
7. Groschel A, Warth A, Reinmuth N. Crizotinib-molecular therapy for lung cancer. Pneumologie (Stuttgart, Germany). 2013;67:205-208.
8. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
9. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33:992-999.
10. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24:2364-2370.
11. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer (Amsterdam, Netherlands). 2014;84:121-126.
12. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378-381.
13. Tsuta K, Kohno T, Yoshida A, et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014;110:1571-1578.
14. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30:4352-4359.
15. Yoo SS, Jin G, Jung HJ, et al. RET fusion genes in Korean non-small cell lung cancer. J Korean Med Sci. 2013;28:1555-1558.
16. Ha SY, Choi SJ, Cho JH, et al. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget. 2015;6:5465-5474.
17. Colen R, Foster I, Gatenby R, et al. NCI Workshop Report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol. 2014;7:556-569.
18. Rizzo S, Petrella F, Buscarino V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur Radiol. 2015;9:[Epub ahead of print], DOI 10.1007/s00330-015-3814-0.
19. Yamamoto S, Korn RL, Oklu R, et al. ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology. 2014;272:568-576.
20. Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16:229-243.
21. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
22. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
23. Simon RM, Subramanian J, Li MC, et al. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011;12:203-214.
24. Pang H, Jung SH. Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. Genet Epidemiol. 2013;37:276-282.
25. Vilmar AC, Sorensen JB. Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev. 2011;20:45-52.
26. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616-4620.
27. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE. 2011;6:e28204.
28. Halpenny DF, Riely GJ, Hayes S, et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer. 2014;86:190-194.
29. Ko SJ, Lee YJ, Park JS, et al. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. BMC Cancer. 2014;14:312.
30. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (Oxford, England: 1990). 2012;48:441-446.
31. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234-1248.
32. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35:1226-1234.
33. Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer (Amsterdam, Netherlands). 2013;79: 242-247.
34. Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol. 2013;10:27-40.
35. Kodama T, Tsukaguchi T, Satoh Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014;13:2910-2918.
36. Huber KV, Salah E, Radic B, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508:222-227.
37. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rear-ranged non-small-cell lung cancer. N Engl J Med. 2014;371: 1963-1971.
38. 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38:1191-1202.
39. Miles KA, Ganeshan B, Griffiths MR, et al. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology. 2009;250:444-452.
40. Ganeshan B, Skogen K, Pressney I, et al. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012;67:157-164.
41. Win T, Miles KA, Janes SM, et al. Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res. 2013;19:3591-3599.